Business Wire

FDA Grants EBR Systems Breakthrough Device Designation Status for the WiSE Cardiac Resynchronization Therapy (CRT) System

SUNNYVALE, Calif.--(BUSINESS WIRE)--EBR Systems, Inc., developer of the world’s only wireless cardiac pacing system for heart failure, today announced that the U.S. Food and Drug Administration (FDA) ...
Medscape

ESC Updates Guidance on Cardiac Pacing, Resynchronization Therapy

The European Society of Cardiology (ESC) has released updated guidelines for cardiac pacing and cardiac resynchronization therapy (CRT), which emphasize patient-centered care and shared ...
Medscape

CARE-HF: Long-term Effects of Cardiac Resynchronization on Mortality and Echocardiography and Cost-effectiveness Analyses

The Cardiac Resynchronization in Heart Failure (CARE-HF) [1] trial was an open-label, randomized, controlled study that evaluated the effects of cardiac resynchronization therapy (CRT) on morbidity ...
TCTMD

Societies Update Appropriate Use Criteria for Cardiac Implantable Devices

Multiple societies covering cardiovascular medicine, electrophysiology, heart failure, and imaging have released updated appropriate use criteria (AUC) for various cardiac implantable electronic ...
MedPage Today

Early CRT Benefits HF With Moderately Reduced Ejection Fraction

BOSTON -- Early cardiac resynchronization therapy (CRT) benefited patients with moderately reduced ejection fraction (EF) and left bundle branch block (LBBB) but no indication for pacing, according to ...
TCTMD

FDA Approves the Optimizer Smart Implantable Pulse Generator for Heart Failure

The Optimizer Smart implantable pulse generator, which delivers cardiac contractility modulation (CCM) therapy, is now approved by the US Food and Drug Administration for the treatment of chronic, ...